Advanced search
Publication Cover
Leukemia & Lymphoma Volume 63, 2022 - Issue 1
Submit an article Journal homepage
1,664
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Increased early mortality after fludarabine and melphalan conditioning with peripheral blood grafts in haploidentical hematopoietic cell transplantation with post-transplant cyclophosphamide

Luke Eastburga University of Rochester Medical Center, Rochester, NY, USAORCID Iconhttps://orcid.org/0000-0001-6123-5848View further author information
ORCID Icon,
David A. Russler-Germainb Division of Oncology, BMT Section, Washington University School of Medicine, St. Louis, MO, USAORCID Iconhttps://orcid.org/0000-0003-1009-2247View further author information
ORCID Icon,
John F. DiPersiob Division of Oncology, BMT Section, Washington University School of Medicine, St. Louis, MO, USAView further author information
,
Thomas Fountainea University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Jeffrey R. Andolinaa University of Rochester Medical Center, Rochester, NY, USAView further author information
,
Ramzi Abboudb Division of Oncology, BMT Section, Washington University School of Medicine, St. Louis, MO, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7786-4155View further author information
ORCID Icon &
Eric Huseltona University of Rochester Medical Center, Rochester, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-3397-7435View further author information
ORCID Icon show all
Pages 222-226 | Received 20 Jun 2021, Accepted 28 Aug 2021, Published online: 18 Nov 2021

References

  • Luznik L, O’Donnell PV, Symons HJ, et al. HLA-Haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008;14(6):641–650.
  • Ciurea SO, Zhang M-J, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(8):1033–1040.
  • Bashey A, Zhang M-J, McCurdy SR, et al. Mobilized peripheral blood stem cells versus unstimulated bone marrow as a graft source for T-Cell–replete haploidentical donor transplantation using post-transplant cyclophosphamide. J Clin Oncol. 2017;35(26):3002–3009.
  • Abboud R, Keller J, Slade M, et al. Severe cytokine-release syndrome after T cell-replete peripheral blood haploidentical donor transplantation is associated with poor survival and anti-IL-6 therapy is safe and well tolerated. Biol Blood Marrow Transplant. 2016;22(10):1851–1860.
  • Abboud R, Wan F, Mariotti J, et al. Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. Bone Marrow Transplant (2021). https://doi.org/https://doi.org/10.1038/s41409-021-01403-w
  • Ciurea SO, Kongtim P, Varma A, et al. Is there an optimal conditioning for older patients with AML receiving allogeneic hematopoietic cell transplantation? Blood. 2020;135(6):449–452.
  • Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118(24):6438–6445.
  • Besien K van, Artz A, Champlin RE, Guarneri D, et al. Haploidentical vs haplo-cord transplant in adults under 60 years receiving fludarabine and melphalan conditioning. Blood Adv. 2019;3(12):1858–1867.
  • Lee DW, Santomasso BD, Locke FL, et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant. 2019;25(4):625–638.
  • Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(12):1835–1844.
  • Imus PH, Blackford AL, Bettinotti M, et al. Severe cytokine release syndrome after haploidentical peripheral blood transplantation. Biol Blood Marrow Transplant. 2019;25(12):2431–2437.
  • Vasu S, Geyer S, Bingman A, et al. Granulocyte colony-stimulating factor–mobilized allografts contain activated immune cell subsets associated with risk of acute and chronic graft-versus-Host disease. Biol Blood Marrow Tr. 2016;22(4):658–668.
  • Mariotti J, Taurino D, Marino F, et al. Pretransplant active disease status and HLA class II mismatching are associated with increased incidence and severity of cytokine release syndrome after haploidentical transplantation with posttransplant cyclophosphamide. Cancer Med. 2020;9(1):52–61.
  • Yamashita T, Takami A, Uchida N, et al. Reduced-intensity stem cell transplantation for acute myeloid leukemia with fludarabine-based conditioning with intravenous busulfan versus melphalan. Bone Marrow Transplant. 2020;55(10):1955–1965.
  • Ghosh N, Ahmed S, Ahn KW, et al. Association of reduced-intensity conditioning regimens with overall survival among patients with non-Hodgkin lymphoma undergoing allogeneic transplant. JAMA Oncol. 2020;6(7):1011–1018.
  • Nath CE, Shaw PJ, Trotman J, et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Brit J Clin Pharmaco. 2010;69(5):484–497.
  • Lu X, Ding Z-C, Cao Y, et al. Alkylating agent melphalan augments the efficacy of adoptive immunotherapy using tumor-specific CD4+ T cells. J Immunol. 2015;194(4):2011–2021.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.